News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
With gender inequality a continued area of focus for corporations and workplaces around the globe, the Healthcare Businesswomen’s Association (HBA) is proud to recognize Otsuka America Pharmaceutical, Inc., and Merck & Co., Inc., for exemplary workplace initiatives working to close the gender gap in the healthcare and life science industries. The awards will be presented on Wednesday, November 10, 2021, in conjunction with HBA’s virtual Annual Conference.
The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company.
The McQuade Center for Strategic Research and Development at Otsuka in the U.S. will support the clinical development of a first-in-class therapeutic with the potential to treat Fragile X syndrome (FXS), a rare, genetic condition that causes intellectual disability, behavioral and learning challenges, and various physical characteristics1.
PRINCETON, NJ – The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Aché Laboratórios Farmacêuticos S.A. (Aché), a leader in the Latin American pharmaceutical market, to co-develop a therapy with the potential to treat general anxiety disorder (GAD) and post-traumatic stress disorder (PTSD).
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces topline outcomes from a phase II clinical trial that evaluated the safety and efficacy of brexpiprazole for the treatment of patients with borderline personality disorder (BPD).